• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

EditCo Bio, Inc. Launches XDel Knockout Cells: Redefining CRISPR Gene Editing Efficiency and Reproducibility

By: EditCo Bio, Inc. via Business Wire
January 28, 2025 at 13:00 PM EST

Novel approach to CRISPR editing in immortalized and iPS cell lines offers an efficient, scalable solution for laboratories wanting to streamline and accelerate their research.

EditCo Bio, a leader in cutting-edge genetic engineering and cellular model solutions, today announced the launch of XDel Knockout Cells, an innovative product designed to revolutionize the field of CRISPR gene editing. By leveraging a groundbreaking guide RNA (gRNA) design strategy, XDel technology ensures robust, reliable, and reproducible gene knockout results that accelerate research in functional genomics, disease modeling, and drug development.

Unmatched Quality and Efficiency

XDel Knockout Cells outperform traditional single-guide RNA (sgRNA) CRISPR methods, delivering significantly higher on-target editing efficiency while minimizing off-target effects. With a unique multiple guide RNA design, XDel technology utilizes up to three intelligently coordinated gRNAs to create efficient and consistent fragment deletions in target genes. This approach ensures persistent protein depletion and eliminates the variability often encountered with single-guide methods.

Key Benefits of XDel Knockout Technology:

  • High Efficiency: Achieve higher on-target editing rates and consistent knockout performance
  • Reliable Results: Persistent protein depletion, validated through functional assays
  • Enhanced Reproducibility: Minimize variability for dependable outcomes across experiments in any loss-of-function study
  • Unparalleled Flexibility: Consistent results in both convenient and efficient cell pools as well as clonal cells

Different Formats and Cell Types to Meet Research Needs

XDel Knockout Cells are available in a variety of customizable formats, including cell pools, cell clones, and engineered cell libraries. Researchers can select from immortalized cells or induced pluripotent stem cells (iPSCs), either customer-supplied or EditCo-supplied, ensuring compatibility with diverse experimental workflows.

Driving Discovery Forward

“XDel Knockout Cells are designed to empower researchers with the confidence and reproducibility they need in guaranteed CRISPR knockouts to drive groundbreaking discoveries with ease,” said Travis Maures, CSO of EditCo Bio. “With novel XDel technology and the freedom to easily order reliable knockout cell pools and clones across cell types, we are setting a new benchmark for CRISPR gene editing, democratizing CRISPR and making complex experiments simpler and more efficient.”

The introduction of XDel Knockout Cells is a strategic extension of EditCo’s comprehensive Engineered Cell portfolio. It further solidifies the company’s position as a leader in cell engineering solutions that includes precision knockout and knock-in technologies across cell types, including immortalized, iPS, and primary cell lines like T cells and fibroblasts.

To learn more about XDel Knockout Cells, visit www.editco.bio or contact EditCo at www.EditCo.bio/contact.

About EditCo Bio, Inc.

EditCo Bio is a pioneer in the development of CRISPR-engineered cell models and high-throughput gene editing solutions. Originally a spinout of Synthego, EditCo Bio leverages the expertise, technology, and partnerships that are critical for creating a novel, end-to-end CRISPR platform able to accelerate scientific discoveries. They’re dedicated to building out a more accessible research toolkit to make genome engineering easier, faster, and more reliable. To learn more about EditCo Bio, visit our website at www.EditCo.bio.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250128927493/en/

Contacts

Media Contacts:

Lindsey Wolf

pr@editco.bio

More News

View More
News headline image
Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport ↗
December 17, 2025
Via MarketBeat
Tickers BHP FCX
News headline image
Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock ↗
December 17, 2025
Via MarketBeat
Topics Initial Public Offering
Tickers GOOGL PL RKLB
News headline image
Can Upwork Maintain Its Comeback? Reasons to Be Bullish and Bearish ↗
December 17, 2025
Via MarketBeat
Tickers BLSH FVRR UPWK
News headline image
Is Tesla Overvalued? 2 Reasons It Might Be a Bargain ↗
December 17, 2025
Via MarketBeat
Tickers TSLA
News headline image
How These 2 Stocks Won 2025's AI Race—And What's In Store for 2026 ↗
December 17, 2025
Via MarketBeat
Topics Artificial Intelligence
Tickers MU STX

Recent Quotes

View More
Symbol Price Change (%)
AMZN  221.27
+0.00 (0.00%)
AAPL  271.84
+0.00 (0.00%)
AMD  198.11
+0.00 (0.00%)
BAC  54.55
+0.00 (0.00%)
GOOG  298.06
+0.00 (0.00%)
META  649.50
+0.00 (0.00%)
MSFT  476.12
+0.00 (0.00%)
NVDA  170.94
+0.00 (0.00%)
ORCL  178.46
+0.00 (0.00%)
TSLA  467.26
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap